(July 20, 2017, 12:53 PM EDT) -- WASHINGTON, D.C. — A Delaware federal judge’s determination of invalidity with regard to various claims of a patented product for the treatment of multiple myeloma and mantle cell lymphoma was erroneous, the Federal Circuit U.S. Court of Appeals ruled July 17 (Millennium Pharmaceuticals Inc. v. Sandoz Inc., et al., Nos. 2015-2066, 2016-1008, -1009, -1010, -1109, -1110, -1283, Fed. Cir., 2017 U.S. App. LEXIS 12702)....